Existing shareholder IP Group has returned to back an $84m series B round for Artios, which also attracted corporates Pfizer, Novartis, AbbVie and Merck Group.
UK-based cancer-focused biotechnology company Artios Pharma raised £65m ($84m) in an oversubscribed series B round today that featured commercialisation firm IP Group.
Investment firms Andera Partners and LSP co-led the round, which also included Pfizer Ventures, Novartis Venture Fund, M Ventures and AbbVie Ventures, respective corporate venturing units of pharmaceutical firms Pfizer, Novartis, Merck Group and AbbVie.
VC firms Arix Bioscience and SV Health Investors also provided capital.
The round is tranched and subject to Artios achieving certain milestones. IP…
